Drug Type AAV based gene therapy |
Synonyms AAVB 081, AAVB081 |
Target |
Mechanism MYO7A inhibitors(myosin VIIA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization AAVantgarde Bio SrlStartup |
Active Organization AAVantgarde Bio SrlStartup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Usher Syndrome, Type 1B | Phase 2 | IT | AAVantgarde Bio SrlStartup | 02 Jul 2024 |
Usher Syndrome, Type 1B | Phase 2 | GB | AAVantgarde Bio SrlStartup | 02 Jul 2024 |
Usher Syndrome, Type Ib | Phase 2 | IT | AAVantgarde Bio SrlStartup | 02 Jul 2024 |
Usher Syndrome, Type Ib | Phase 2 | GB | AAVantgarde Bio SrlStartup | 02 Jul 2024 |